Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

BACKGROUND: Avelumab (MSB0010718C) is a human IgG1 monoclonal antibody that binds to PD-L1, inhibiting its binding to PD-1, which inactivates T cells. We aimed to establish the safety and pharmacokinetics of avelumab in patients with solid tumours while assessing biological correlatives for future d...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet Oncol
Hlavní autoři: Heery, Christopher R, O’Sullivan-Coyne, Geraldine, Madan, Ravi A, Cordes, Lisa, Rajan, Arun, Rauckhorst, Myrna, Lamping, Elizabeth, Oyelakin, Israel, Marté, Jennifer L, Lepone, Lauren M, Donahue, Renee N, Grenga, Italia, Cuillerot, Jean-Marie, Neuteboom, Berend, von Heydebreck, Anja, Chin, Kevin, Schlom, Jeffrey, Gulley, James L
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6387686/
https://ncbi.nlm.nih.gov/pubmed/28373007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30239-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky